Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
Sponsor: Andrulis Pharmaceuticals
A PHASE2 clinical study on HIV Infections and Stomatitis, Aphthous, this trial is completed. The trial is conducted by Andrulis Pharmaceuticals and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Andrulis Pharmaceuticals
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United States, Boston, United States, Buffalo, United States, Chapel Hill, United States, Chicago, United States, Cleveland, United States, Denver, United States, Hershey, United States, Honolulu, United States, Indianapolis, United States and 12 more location s